Related Experiment Video
Updated: Jul 27, 2026
13:01
Anti-Nuclear Antibody Screening Using HEp-2 Cells
Published on: June 23, 2014
Anti-Sm: its predictive value in systemic lupus erythematosus
S Janwityanuchit1, O Verasertniyom, M Vanichapuntu
1Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Clinical Rheumatology
|September 1, 1993
Summary
The anti-Sm antibody is exclusively found in systemic lupus erythematosus (SLE) when anti-double stranded DNA (anti-dsDNA) is also present. Anti-Sm antibody presence may help predict SLE clinical outcomes.
Area of Science:
- Rheumatology
- Immunology
- Clinical Medicine
Background:
- Anti-Sm antibody is a biomarker associated with rheumatic diseases.
- Understanding the clinical significance of anti-Sm antibody in conjunction with other autoantibodies is crucial for disease diagnosis and management.
Purpose of the Study:
- To investigate the clinical manifestations of rheumatic disease patients with anti-Sm antibody.
- To determine the diagnostic and prognostic value of anti-Sm antibody in systemic lupus erythematosus (SLE).
Main Methods:
- Utilized FANA test for antinuclear antibodies (ANA), Crithidia test for anti-double stranded DNA (anti-dsDNA), and double immunodiffusion for extractable nuclear antigens.
- Grouped 131 patients based on the presence of anti-Sm alone or with other antibodies (anti-RNP, anti-dsDNA).
Main Results:
- Anti-Sm antibody was exclusively detected in SLE patients when anti-dsDNA was also present.
- SLE patients with anti-Sm alone showed more frequent central nervous system manifestations.
- Renal manifestations were more common in SLE patients with anti-Sm and anti-dsDNA (92.9%).
- Hematologic involvement was less common in patients with anti-Sm alone.
Conclusions:
- Anti-Sm antibody, particularly with anti-dsDNA, is a significant indicator for SLE.
- The presence of anti-Sm antibody can aid in predicting specific clinical manifestations and outcomes in SLE patients.
